Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
The Zacks Consensus Estimate for sales and earnings is pegged at $119.1 million and 16 cents per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Earnings estimate for 2025 has increased to 71 cents from 69 cents per share over the past 60 days, and the same for 2026 has improved to 93 cents from 87 cents.
Zacks Investment Research
Image Source: Zacks Investment Research
ADMA's Earnings Surprise History
ADMA has a mixed track record. Its earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 32.8%. However, in the previously reported quarter, the company's earnings missed estimates by 6.67%.
Zacks Investment Research
Image Source: Zacks Investment Research
What Our Model Predicts for ADMA
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP for ADMA is 0.00%. The company currently carries a Zacks Rank #2. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Factors Influencing ADMA's Q1 Results
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company's top line currently comprises sales of three FDA-approved products, which are Bivigam (an Intravenous Immune Globulin [IVIG] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies.
These antibodies are proteins used by the body's immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease.
Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company's proprietary microneutralization assay.
Increased sales of Asceniv have likely fueled the top line in the first quarter. Gross margin has also likely improved due to a significantly more favorable mix of high margin immunoglobulin (IG) sales.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why The PNC Financial Services Group, Inc (PNC) is a Great Dividend Stock Right Now
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus. Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases. The PNC Financial Services Group, Inc (PNC) is headquartered in Pittsburgh, and is in the Finance sector. The stock has seen a price change of 0.07% since the start of the year. The company is paying out a dividend of $1.70 per share at the moment, with a dividend yield of 3.52% compared to the Financial - Investment Bank industry's yield of 1.02% and the S&P 500's yield of 1.49%. Looking at dividend growth, the company's current annualized dividend of $6.80 is up 7.9% from last year. Over the last 5 years, The PNC Financial Services Group, Inc has increased its dividend 3 times on a year-over-year basis for an average annual increase of 8.49%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. The PNC Financial Services Group's current payout ratio is 44%, meaning it paid out 44% of its trailing 12-month EPS as dividend. Earnings growth looks solid for PNC for this fiscal year. The Zacks Consensus Estimate for 2025 is $15.50 per share, representing a year-over-year earnings growth rate of 11.43%. Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. But, not every company offers a quarterly payout. High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. With that in mind, PNC is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The PNC Financial Services Group, Inc (PNC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why CNA Financial (CNA) Might be Well Poised for a Surge
CNA Financial (CNA) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this insurance holding company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008. For CNA Financial, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year. The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate: 12 Month EPS Current-Quarter Estimate Revisions The company is expected to earn $1.17 per share for the current quarter, which represents a year-over-year change of +8.3%. The Zacks Consensus Estimate for CNA Financial has increased 5.91% over the last 30 days, as one estimate has gone higher compared to no negative revisions. Current-Year Estimate Revisions The company is expected to earn $4.49 per share for the full year, which represents a change of -7.0% from the prior-year number. There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, two estimates have moved up for CNA Financial versus no negative revisions. This has pushed the consensus estimate 7.29% higher. Favorable Zacks Rank The promising estimate revisions have helped CNA Financial earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500. Bottom Line While strong estimate revisions for CNA Financial have attracted decent investments and pushed the stock 8.6% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CNA Financial Corporation (CNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
STRW vs. OHI: Which Stock Should Value Investors Buy Now?
Investors interested in REIT and Equity Trust - Other stocks are likely familiar with Strawberry Fields REIT, Inc. (STRW) and Omega Healthcare Investors (OHI). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Both Strawberry Fields REIT, Inc. and Omega Healthcare Investors have a Zacks Rank of #2 (Buy) right now. Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. However, value investors will care about much more than just this. Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels. Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use. STRW currently has a forward P/E ratio of 9.20, while OHI has a forward P/E of 13.65. We also note that STRW has a PEG ratio of 1.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. OHI currently has a PEG ratio of 2.74. Another notable valuation metric for STRW is its P/B ratio of 2.18. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, OHI has a P/B of 2.35. These metrics, and several others, help STRW earn a Value grade of A, while OHI has been given a Value grade of D. Both STRW and OHI are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that STRW is the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Strawberry Fields REIT, Inc. (STRW) : Free Stock Analysis Report Omega Healthcare Investors, Inc. (OHI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
